Sunshine Biopharma Announces 1-for-10 Reverse Stock Split to Maintain NASDAQ Listing
SBFM sits 47% above its 52-week low of $0.281.
Summary
Sunshine Biopharma announced a 1-for-10 reverse stock split, effective June 1, 2026, to regain NASDAQ minimum bid price compliance. This follows recent worsening financials, including increased losses and cash burn reported in the May 13th 10-Q, and a highly dilutive $6 million offering finalized on May 19th. While necessary for listing, reverse splits for micro-cap companies often indicate significant financial distress and can lead to further selling pressure. Traders should monitor post-split price action and any future capital raises.
At the time of this announcement, SBFM was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1M. The 52-week trading range was $0.28 to $2.43. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: ACCESS Newswire.